KOKRYSZTAŁY – NOWA FORMA LEKU

Agnieszka Sokal; Edyta Pindelska

doi:10.56782/pps.96

Published : 2013-05-08

Vol. 11 No. 5 (2013)

COCRYSTALS - A NEW DRUG FORM

Agnieszka Sokal

Edyta Pindelska

DOI: https://doi.org/10.56782/pps.96

Abstract

Cocrystallization was already known 160 years ago. Cocrystals are structurally homogeneous crystalline materials containing two or more components present in definite stoichiometric amounts. The components are discrete neutral molecular species which are solids at ambient temperature. The use of cocrystallization to generate new forms of active pharmaceutical ingredients (API) was initiated only at the end of the last century. In recent years, the number of publications on this topic has increased significantly, mainly because of the possibility of replacing poorly soluble salts of biologically active substances with their cocrystals. Of particular importance are the physicochemical properties of cocrystals which, when modified, alter the pharmacodynamic parameters of the cocrystallized drug. It is possible to improve the solubility, stability, and – in particular – the bioavailability of drugs.

Keywords:

cocrystals, cocrystallization, pharmaceutical cocrystals, API, methods of cocrystallization

Similar Articles

Andrzej Patyra, Marcin Kołakowski, Marta Katarzyna Dudek, Anna Karolina Kiss, Isolation of trachelogenin 4-O-β-D-glucoside from the fruits of Carthamus tinctorius L. , Prospects in Pharmaceutical Sciences: Vol. 20 No. 2 (2022)
Małgorzata Krzyżanowska, Katarzyna Kozon, Jakub Olszewski, Andrzej Patyra, Efficacy of satralizumab therapy in the treatment of NMOSD , Prospects in Pharmaceutical Sciences: Vol. 21 No. 3 (2023)
Kinga Grużewska-Piotrowska, Agnieszka Grużewska, Medication overuse headache as a consequence of taking painkillers – a review of current literature , Prospects in Pharmaceutical Sciences: Vol. 21 No. 3 (2023)
Marta Oleszczuk, NUCLEAR MAGNETIC RESONANCE IN THE STRUCTURAL INVESTIGATION OF BIOMOLECULES: APPLICATION IN THE STUDY OF MODEL HELICAL SYSTEMS , Prospects in Pharmaceutical Sciences: Vol. 4 No. 1 (2006)
Andrzej Tokarz, Małgorzata Jelińska, Agnieszka Ozga, ISOPROSTANES - NEW BIOMARKERS IN LIPID PEROXIDATION IN VIVO , Prospects in Pharmaceutical Sciences: Vol. 2 No. 2 (2004)
Tomasz Pieńko, CAPSAICIN – PROPERTIES, APPLICATIONS TODAY AND FUTURE PROSPECTS , Prospects in Pharmaceutical Sciences: Vol. 11 No. 2 (2013)

<< < 1 2 3 4 5 6

You may also start an advanced similarity search for this article.

Details

References

Statistics

Authors

Download files

PDF (Język Polski)

Citation rules

Sokal, A., & Pindelska, E. (2013). COCRYSTALS - A NEW DRUG FORM. Prospects in Pharmaceutical Sciences, 11(5), 37–41. https://doi.org/10.56782/pps.96

Altmetric indicators

Cited by / Share

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

Friscic T., Jones W.: Benefits of cocrystalisation in pharmaceutical materials science: an update, Jourmal of Pharmacy and Pharmacology, 2010, 62, 1547-1559. DOI: https://doi.org/10.1111/j.2042-7158.2010.01133.x

Cheney M. L., Weyna D. R.,Shan N., Mazen H., Wojas Ł., Zaworotko M. J.: Supramolecular architectures of meloxicam carboxylic acid cocrystals, a crystal engineering case study, Crystal Growth and Design, 2010, 10, 4401-4413. DOI: https://doi.org/10.1021/cg100514g

Dunitz J. D.: Crystal and co-crystal: a second opinion, Crystal Engeeniring Communications, 2003, 5, 506-506. DOI: https://doi.org/10.1039/b315687g

Desiraju G. R.: Crystal and co-crystal, Crystal Engeenering Communications, 2003, 5, 466-467. DOI: https://doi.org/10.1039/b313552g

Bond A. D.: What is a co-crystal? Crystal Engeenering Communications, 2007, 9, 833-834. DOI: https://doi.org/10.1039/b708112j

Aakeröy C. B., Salmon D. J.: Building co-crystals with molecular sense and supramolecular sensibility, Crystal Engeenering Communications, 2005, 7,439-448. DOI: https://doi.org/10.1039/b505883j

Qiao N., Schlindwein W., Malek N., Davis A., Trappitt G.: Pharmaceutical cocrystals: an overview, International Journal of Pharmaceutics, 2011. 419, 1-11. DOI: https://doi.org/10.1016/j.ijpharm.2011.07.037

Dario Broga F. G.: Making Crystal by Design, Wiley-VCH Verlag GmbH & Co, KGaA, Weinheim, 2006.

Yadav A. V., Shete A. S., Dabke A. P., Kulkarni P. V., Sakhare S. S.: Co-crystals: A novel approach to modify physicochemical properties of active pharmaceutical ingredients, Indian Journal of Pharmaceutical Sciences, 2009, 71, 370-359. DOI: https://doi.org/10.4103/0250-474X.57283

Ling A. R., Baker J. L.: XCVI.—Halogen derivatives of quinone. Part III. Derivatives of quinhydrone, Journal of the Chemical Society, 1893, 63, 1314-1327. DOI: https://doi.org/10.1039/CT8936301314

Chadwick K., Davey R., Cross W.: How does grinding produce co-crystals? Insights from the case of benzophenone and diphenylamine, Crystal Engeenering Communications, 2007, 9, 732-734. DOI: https://doi.org/10.1039/b709411f

Karki S., Friščić T., Jones W., Motherwell W. D. S.: Screening for pharmaceutical cocrystal hydrates via neat and liquid-assisted grinding, Molecular Pharmaceutics, 2007, 4, 347-354. DOI: https://doi.org/10.1021/mp0700054

Lien Nguyen K., Friščić T., Day G. M., Gladden L. F., Jones W.: Terahertz time-domain spectroscopy and the quantitative monitoring of mechanochemical cocrystal formation, Nature Materials, 2007, 6, 206-209. DOI: https://doi.org/10.1038/nmat1848

Rastogi R., Bassi P.S., Chadha S.: Mechanism of the reaction between hydrocarbons and picric acid in the solid state, Journal of Physical Chemistry, 1963, 67, 2569-2573. DOI: https://doi.org/10.1021/j100806a016

Shan N., Toda F., Jones W.: Mechanochemistry and cocrystal formation: efect of solvent on reaction kintetics, Chem. Commun. (Camb.), 2002, 20, 2372-2373.

Jayasankar A., Samwangthanaroj A., Shao Z. J., Rodriguez-Hornedo N.: Cocrystal formation during cogrinding and storage is mediated by amorphous phase, Pharmaceutical Research, 2006, 23, 2381-2392. DOI: https://doi.org/10.1007/s11095-006-9110-6

Friščić T., Jones W.: Recent advances in understanding the mechanism of cocrystal formation via grinding, Crystal Growth and Design, 2009, 1621-1637. DOI: https://doi.org/10.1021/cg800764n

Seefeldt K., Miller J., Alvarez-Nunez F., Rodriguez-Hornedo N.: Crystallization pathways and kinetics of carbamazepine–nicotinamide cocrystals from the amorphous state by in situ thermomicroscopy, spectroscopy, and calorimetry studies, Journal of Pharmaceutical Sciences, 2007, 96, 1147-1158. DOI: https://doi.org/10.1002/jps.20945

Shan N., Toda F., Jones W.: Mechanochemistry and co-crystal formation: effect of solvent on reaction kinetics, Chemical Communications, 2002(20), 2372-2373. DOI: https://doi.org/10.1039/b207369m

Friščić T., Childs S. L., Rizvi S. A. A., Jones W.: The role of solvent in mechanochemical and sonochemical cocrystal formation: a solubility-based approach for predicting cocrystallisation outcome, Crystal Engeenering Communications, 2009, 11, 418-426. DOI: https://doi.org/10.1039/B815174A

Blagden N., Berry D. J., Parkin A., Javed H., Ibrahim A., Gavan P. T., De Matos L. L., Seaton C. C.: Current directions in co-crystal growth, New Journal of Chemistry, 2008, 32(10), 1659-1672. DOI: https://doi.org/10.1039/b803866j

Dhumal R. S., Biradar S. V., Paradkar A. R., York P.: Ultrasound assisted engineering of lactose crystals, Pharmaceutical Research, 2008, 25, 2835-2844 DOI: https://doi.org/10.1007/s11095-008-9653-9

Lipinski C.A.: Solubility in water and DMSO: Issues and potential solutions, AAPS Press, Arlington, USA, 2004.

Takagi T., Ramachandran C., Bermeio M., Yamashita S., Yu L. X., Amidon G. L.: A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan, Molecular Pharmaceutics, 2006, 3, 631-643 DOI: https://doi.org/10.1021/mp0600182

Good D. J., Rodríguez-Hornedo N.: Solubility advantage of pharmaceutical cocrystals, Crystal Growth and Design, 2009. 9, 2252-2264. DOI: https://doi.org/10.1021/cg801039j

Rasenack N., Hartenhauer H., Muller B. W.: Microcrystals for dissolution rate enhancement of poorly water-soluble drugs, International Journal of Pharmaceutics, 2003, 254, 137-145. DOI: https://doi.org/10.1016/S0378-5173(03)00005-X

Li Z. J., Abramow Y., Bordner J., Leonard J., Medek A., Trask A. V.: Solid-state acid-base interactions in complexes of heterocyclic bases with dicarboxylic acids: Crystallography, hydrogen bond analysis, and 15N NMR spectroscopy, Journal of the American Chemical Society, 2006, 128, 8199-8210. DOI: https://doi.org/10.1021/ja0541332

Hong J. Y., Kim J. K., Song Y. K., Park J. S., Kim C. K.: A new self-emulsifying formulation of itraconazole with improved dissolution and oral absorption, Journal of Controlled Release, 2006, 110, 332-338. DOI: https://doi.org/10.1016/j.jconrel.2005.10.002

Umeda Y., Fukami T., Furuishi T., Suzuki T., Tanjoh K., Tomono K.: Characterization of multicomponent crystal formed between indomethacin and lidocaine, Drug Development and Industrial Pharmacy, 2009, 35, 843-851. DOI: https://doi.org/10.1080/03639040802660489

Schultheiss N., Newman A.: Pharmaceutical cocrystals and their physicochemical properties, Crystal Growth and Design, 2009, 9, 2950-2967. DOI: https://doi.org/10.1021/cg900129f

Aakeröy C. B., Fasulo M. E., Desper J.: Cocrystal or salt: does it really matter? Molecular Pharmaceutics, 2007, 4, 317-322. DOI: https://doi.org/10.1021/mp060126o

McNamara D. P., Childa S. L., Giordani J., Iarriccio A., Cassidy J., Shet M. S., Mannion R., O’Donnell E., Park A.: Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API, Pharmaceutical Research, 2006, 23, 1888-1897. DOI: https://doi.org/10.1007/s11095-006-9032-3

Agnieszka Sokal

Affiliation:

Koło naukowe „Spectrum” przy Katedrze i Zakładzie Chemii Nieorganicznej i Analitycznej Poland

Edyta Pindelska

Affiliation:

Katedra i Zakład Chemii Nieorganicznej i Analitycznej, Wydział Farmaceutyczny Warszawski Uniwersytet Medyczny Poland